Organisation paid for research Program year 2025 Source: CMS Open Payments

Ciocca Dermatology

Neither a doctor nor a teaching hospital

Research payments

$1,382,250

54 payments

Through program year 2025, Ciocca Dermatology is reported as receiving $1,382,250 in research payments, across 54 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$257,167	3
2024	Research	$242,345	5
2023	Research	$98,220	3
2022	Research	$43,957	4
2021	Research	$517,971	13
2020	Research	$222,058	24
2019	Research	$531	2

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $1,379,475 46 payments
Sanofi US Services Inc. $1,544 4 payments
Genzyme Corporation $700 2 payments
Celgene Corporation $461 1 payment
Pfizer Inc. $70 1 payment

Studies the money was for Research payments · program years 2019–2025

PPSO-004/20200057 (SPROUT Rollover) $261,793 2 payments
Ppso-003/20200056 (Sprout) $242,719 2 payments
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis $214,472 2 payments
Efficacy/Safety Study of Apremilast in Pedi Subjects With Moderate to Severe Plaque PSO (PPSO-003) $206,750 21 payments
Ph3b Otezla in Peds mod/sev PsO SPROUT rollover $154,645 1 payment
Ph3b Otezla in Peds mod/sev PsO (SPROUT rollover) $80,475 2 payments
Ph3 Otezla in Peds mild/mod PsO PMR $75,985 2 payments
A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis $42,696 1 payment
Ph3 Otezla in Peds mod/sev PsO (SPROUT) $39,834 2 payments
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psor $29,037 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.